Sprint Cup driver Jeremy Mayfield’s explanation that two allowed medications combined may have resulted in a failed drug test isn’t plausible, NASCAR’s substance abuse policy administrator told to a newspaper.
“What we have is a clear violation of policy,” David Black said, according to the newspaper. “In my many years of experience, I have never seen a violation like this due to the combination of over-the-counter or prescription products.”
Black, whose Tennessee-based Aegis Labs runs NASCAR’s drug-testing program, wouldn’t divulge what drug Mayfield tested positive for, only saying it was “a drug of concern,” the report said. ESPN
The driver and owner of the No.41 Toyota finished 35th at Richmond, but failed to qualify for the Southern 500 at Darlington Raceway on Friday.
Mayfield released a statement Saturday evening:
“As both a team owner and a driver in the NASCAR Sprint Cup Series, I have immense respect for the enforcement policies NASCAR has in place. In my case, I believe that the combination of a prescribed medicine and an over the counter medicine reacted together and resulted in a positive drug test. My doctor and I are working with both Dr. Black and NASCAR to resolve this matter.” Auto Racing Daily
| 
|